article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

A market report has projected that the global oral solid dosage (OSD) contract manufacturing market is expected to be worth $54.7 Data showed that worldwide, oral solids are the most popular mode of drug delivery due to being highly cost-effective and offering simple manufacturing processes.

article thumbnail

Less Is More—A Sharper Focus on Patient Needs Improves Adherence

PM360

“Drugs don’t work in patients who don’t take them,” C. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. 1 In addition, of patients who began therapy, more than 70% were no longer on their prescribed medication after 12 months. Everett Koop, MD, U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

First patients given lab-grown blood cell transfusion

European Pharmaceutical Review

Lab-grown blood cells have been transfused into a second patient in the world’s first-of-a-kind clinical trial , opening up future treatments for blood disorders such as sickle cell if found safe and effective. They anticipate patients who need regular blood transfusions could require fewer transfusions over time.

Patients 110
article thumbnail

Three-dose vaccine prevents HIV patients getting hepatitis B

European Pharmaceutical Review

Clinical trial results presented at the US IDWeek conference, revealed a three-dose series of the HEPLISAV-B vaccine prevents hepatitis B virus (HBV) in HIV patients not previously vaccinated against or infected with the virus. A breakdown of the data showed: HbsAb levels were greater than 1000mIU/ml in 88 percent of patients.

article thumbnail

“Game-changing” obesity drug over-promising?

World of DTC Marketing

Patients want quick fixes, and the idea of losing some weight because of a new drug is enticing to them. In response, the company has been providing six-month waivers to some insured patients that will cap the drug’s out-of-pocket costs at $25 a month, though the long-term picture of coverage is still in flux. Click to Tweet.

Insurance 271
article thumbnail

AI-Designed Custom Knee Implants

Medgadget

Scientists at the University of Birmingham in the UK have trialed Generative Design, a design approach that relies on machine learning and artificial intelligence, to create patient-specific knee implants. They then used an electron beam powder bed fusion to manufacture their designs.

article thumbnail

Early cell therapy successes start to turn the tide in lupus

Pharmaceutical Technology

In September, a group from Friedrich Alexander University Erlangen-Nuremberg reported that five patients with lupus achieved remission after an infusion of autologous chimeric antigen receptor (CAR)-T cells led to a deep depletion of B cells. All five patients achieved remission after three months.